PMID- 10864982
OWN - NLM
STAT- MEDLINE
DCOM- 20000912
LR  - 20220330
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 40
IP  - 6
DP  - 2000 Jun
TI  - Combined administration of G-CSF and dexamethasone for the mobilization of 
      granulocytes in normal donors: optimization of dosing.
PG  - 642-4
AB  - BACKGROUND: The clinical utility of neutrophil (polymorphonuclear leukocyte, PMN) 
      transfusion therapy has been compromised, in part, by the inability to obtain 
      sufficient quantities of functional neutrophils from donors. Mobilization of PMNs 
      in the peripheral blood of normal volunteers has been shown to be superior when 
      G-CSF is administered in conjunction with dexamethasone to that when either agent 
      is administered alone. The current study was conducted to determine the optimal 
      dosages of G-CSF and dexamethasone to be administered to donors in a granulocyte 
      transfusion program. STUDY DESIGN AND METHODS: Five normal subjects were randomly 
      assigned to each of the following single-dose regimens over five consecutive 
      weeks: 1) subcutaneous (SC) G-CSF at 600 microg and oral (PO) dexamethasone at 8 
      mg; 2) SC G-CSF at 450 microg and PO dexamethasone at 8 mg; 3) SC G-CSF at 450 
      microg and PO dexamethasone at 12 mg; 4) SC G-CSF at 450 microg; and 5) PO 
      dexamethasone at 12 mg. Venous blood was collected at 0, 6, 12, and 24 hours 
      after drug administration for determination of absolute neutrophil count (ANC). 
      Side effects of drug administration were recorded by using a standardized symptom 
      questionnaire. RESULTS: Maximal ANC was achieved at 12 hours after administration 
      of drugs under each regimen. All four regimens containing G-CSF caused greater 
      than 10-fold increases in the ANC. When administered in conjunction with 
      dexamethasone, G-CSF resulted in statistically similar PMN mobilization at 
      dosages of 450 microg and 600 microg. The combined single-dose regimen of SC 
      G-CSF at 450 microg and PO dexamethasone at 8 mg increased the mean ANC from a 
      baseline value of 2800 per microL to 37,900 per microL at 12 hours after 
      administration. This regimen was well tolerated by the normal volunteers. 
      CONCLUSION: In a single-dose format designed for clinical granulocyte transfusion 
      programs, optimal PMN mobilization can be achieved in normal donors with a 
      combined regimen of SC G-CSF at 450 microg, and PO dexamethasone at 8 microg.
FAU - Liles, W C
AU  - Liles WC
AD  - Department of Medicine, University of Washington, Seattle, Washington 98195-7185, 
      USA.
FAU - Rodger, E
AU  - Rodger E
FAU - Dale, D C
AU  - Dale DC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Recombinant Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - *Blood Donors
MH  - Dexamethasone/administration & dosage/adverse effects/*pharmacology
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage/adverse 
      effects/*pharmacology
MH  - *Granulocytes
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Leukocyte Count/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Pain/chemically induced
MH  - Recombinant Proteins/administration & dosage/adverse effects/pharmacology
MH  - Sleep Initiation and Maintenance Disorders/chemically induced
EDAT- 2000/06/24 11:00
MHDA- 2000/09/19 11:01
CRDT- 2000/06/24 11:00
PHST- 2000/06/24 11:00 [pubmed]
PHST- 2000/09/19 11:01 [medline]
PHST- 2000/06/24 11:00 [entrez]
AID - 10.1046/j.1537-2995.2000.40060642.x [doi]
PST - ppublish
SO  - Transfusion. 2000 Jun;40(6):642-4. doi: 10.1046/j.1537-2995.2000.40060642.x.